3rd Quarter - Report
JAZZ PHARMACEUTICALS, INC. for JAZZ PHARMACEUTICALS, INC.
Client
Income
—
Expenses
$550,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
FDA regulation of CBD FDA Rare Disease PPRV program/reauthorization Issues related to the regulation of cannabis and CBD, research and development of cannabis-derived therapies Most Favored Nation drug pricing Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act HR 946: Orphan Cures Act Legislation Related to the Repeal or Reform of Orphan Cures Section 232 Tariffs
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK BOLTON | — |
| KARAS GROSS | — |
| VIRGINIA MCMILLIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.